Source: Ophthalmology
Area: News
Six-month results from the COPERNICUS study evaluating intravitreal aflibercept ophthalmic solution (VEGF Trap-Eye) in the treatment of macular oedema secondary to central retinal vein occlusion (CRVO) have now been fully published. These results were previously reported at conference at the end of 2010 (see related NeLM report at the link below).
COPERNICUS is an ongoing, 2-year double-blind RCT study being conducted at 70 sites in the United States, Canada, India, Israel, Argentina, and Colombia. Participants have macular oedema secondary to CRVO diagnosed within 9 months of study entry, and a best-corrected visual acuity (BCVA) of 20/40 to 20/320 (ETDRS letters of 73-24) in the study eye. They were randomised to treatment with intravitreal aflibercept ophthalmic solution (2mg; n=115) or sham injection (n=74) every four weeks for 24 months. Patients in both groups were evaluated monthly between weeks 24 and 52, and re-injected with ...
Uncategorized